Weighing in on Lilly’s tirzepatide vials

Medscape wonders how Lilly’s making tirzepatide available in vials will affect the GLP-1 market. Eli Lilly, of course, spewed its usual fearmongering about compounded versions, but Scott didn’t rise to the bait, but did point out that actually helping patients is a welcome change for Lilly.

You’ve probably seen the news that Eli Lilly will begin selling Zepbound in vials by mail. What you...

In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great...

APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the...

Weighing in on Lilly’s tirzepatide vials

Related posts

Scott on Lilly on GLP-1s on CBS

Inside Health Policy quotes Scott (again)

Video: APC on Scripps